Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 6 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

• PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .CompletedNCT03275506Phase 2Report a problem
• Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung CancerStatus unknownNCT03253068Phase 2Report a problem
• Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast CancerTerminatedNCT03225547Phase 2Report a problem
• Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2Report a problem
• Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine CancerCompletedNCT03192059Phase 2Report a problem
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialCompletedNCT03158935Phase 1Report a problem
• Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2Report a problem
• Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)WithdrawnNCT03114280Phase 1/2Report a problem
• A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and StomachWithdrawnNCT02943603Phase 2Report a problem
• Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by SurgeryCompletedNCT02930902Phase 1Report a problem
• Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2Report a problem
• Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)Active, not recruitingNCT02872025Early Phase 1Report a problem
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2Report a problem
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2Report a problem
• Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2Report a problem
• Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic MelanomaActive, not recruitingNCT02617849Phase 2Report a problem
• Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2Report a problem
• Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bCompletedNCT02339324Phase 1Report a problem
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1Report a problem
• Treatment of Advanced Melanoma With MK-3475 and PeginterferonCompletedNCT02112032Phase 1Report a problem
• Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1Report a problem

← Pembrolizumab